PExA AB

PExA offers a patented, non-invasive technology to collect biomarkers from the small airways of the lung via exhaled air. The method is used globally by universities, hospitals, pharmaceutical companies, CROs and government agencies in the US and Europe, among others – in research on asthma, COPD, lung cancer, occupational exposure and pharmacokinetics. The company's goal is to enable earlier diagnosis and screening of lung diseases. PExA was founded in 2014 and is headquartered in Gothenburg.

Quotes for PExA AB

Right Now

+/-
%
0,00%
Latest
High
Low
Volume
0
Turnover (SEK)
0
Market Value (MSEK)
31,6
Time (Latest trade)

Board

CEO

  • Tomas Gustafsson

Chairperson of the Board

  • Claes Holmberg

Board

  • Anna-Carin Olin
  • Björn Dahlöf
  • Martin Malmström
  • Articles of association

    • News

    Show More

    News agencies

    Show More

    Analysis

    Videos

    Pexa - Q3 Presentation 2025

    PExA

    Intervju med VD, Tomas Gustafsson

    Lifesciencedagen 2025 - Pexa

    Largest Owners

    Name Capital % Votes % Date
    Nordnet Pensionsförsäkring 19,33 18,74 2025-09-26
    Avanza Pension 10,17 9,86 2025-09-26
    Daniel Nilsson privat och genom närstående 8,58 8,32 2025-09-23
    Sven Christer Andersson 8,21 7,96 2025-09-26
    Ola Hermansson 5,11 5,14 2025-09-26
    Per Berger 2,42 2,34 2025-09-26
    Anna-Carin Olin 1,82 4,07 2025-09-26
    Mikael Blihagen 1,74 1,69 2025-09-26
    Patrick Svensson 1,17 1,13 2025-09-26
    Jörgen Östling 1,15 1,11 2025-09-26
    ** Powered by Modular Finance

    Insider trading

    *Powered by Modular Finance

    Key Numbers

    *Compiled data from Millistream

    Upcoming reports

    • 2026-02-19 Annual Report 2025

    Annual reports, prospectus etc.